Why the study?
Does hydralazine treatment in utero and postnatally prevent structural alterations in the mesenteric vasculature of spontaneously hypertensive rats?
Population
Male Wistar-Kyoto spontaneously hypertensive rats (SHR) and Wistar-Kyoto normotensive (WKY) rats
Comparison
Hydralazine treatment in utero and postnatally… vs Untreated SHR and untreated WKY rats
Design
Preclinical
Follow-up
up to 28 weeks of age
Authors
Loading...
Early hydralazine fails to prevent vascular remodeling in SHR despite BP control; leaves open pressure-independent mechanisms in genetic hypertension.
Does hydralazine treatment in utero and postnatally prevent structural alterations in the mesenteric vasculature of spontaneously hypertensive rats?
Structural vascular alterations in spontaneously hypertensive rats appear to be an inherent characteristic that cannot be fully reversed merely by normalizing blood pressure with hydralazine from early development.
Smeda et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: